RxDoctor Payments Data

Christine Bao, MD

Family Medicine · Norcross, GANPI 1831175132

Payments from drug & device makers

$7,837in general payments, 2019–2025

Across 291 payments — averaging $26.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$1K
  • AstraZeneca$827
  • GSK$811
  • Amarin Pharma, Inc.$446
  • Gilead$419
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$7,798100%
  • Education$240%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,837 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$219,592
Medicare patients
207
Services billed
4,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab61$101,893
FarxigaDapagliflozin Propanediol77$69,987
JardianceEmpagliflozin77$69,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$45,339
EliquisApixaban38$43,253
VemlidyTenofovir Alafenamide23$35,676
XareltoRivaroxaban19$24,407
OzempicSemaglutide15$22,747
VascepaIcosapent Ethyl22$18,389
KerendiaFinerenone27$18,060
RybelsusSemaglutide13$13,522
Tenofovir Disoproxil Fumarate41$8,585
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,359
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,564
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$1,062$101,89361 claims
AstraZenecaFarxiga$827$69,98777 claims
Boehringer IngelheimJardiance$64$69,42977 claims
GSKTrelegy Ellipta, Shingrix$811$49,77874 claims
PfizerEliquis$238$43,25338 claims
Novo NordiskOzempic, Rybelsus$1,077$36,26928 claims
GileadVemlidy$419$35,67623 claims
Johnson & JohnsonXarelto$142$24,40719 claims
BayerKerendia$129$18,06027 claims
MerckSteglatro$64$3,84511 claims
AbbVieSynthroid$409$1,53411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →